International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorders

…, K Anderson, M Gertz, JL Harousseau, M Attal, P Tosi… - Leukemia, 2009 - nature.com
The serum immunoglobulin-free light chain (FLC) assay measures levels of free κ and λ
immunoglobulin light chains. There are three major indications for the FLC assay in the …

[PDF][PDF] Renal impairment in patients with multiple myeloma: a consensus statement on behalf of the International Myeloma Working Group

…, KC Anderson, P Sonneveld, P Tosi… - Journal of clinical …, 2010 - academia.edu
Renal impairment is a common complication of multiple myeloma (MM). The estimated
glomerular filtration rate (eGFR) using the Modification of Diet in Renal Disease formula is …

International myeloma working group consensus statement and guidelines regarding the current role of imaging techniques in the diagnosis and monitoring of …

M Dimopoulos, E Terpos, RL Comenzo, P Tosi… - Leukemia, 2009 - nature.com
Several imaging technologies are used for the diagnosis and management of patients with
multiple myeloma (MM). Conventional radiography, computed tomography (CT), magnetic …

International uniform response criteria for multiple myeloma

…, G Merlini, R Powles, P Richardson, K Shimizu, P Tosi… - Leukemia, 2006 - nature.com
New uniform response criteria are required to adequately assess clinical outcomes in
myeloma. The European Group for Blood and Bone Marrow Transplant/International Bone …

[PDF][PDF] International staging system for multiple myeloma

…, K Shimizu, C Shustik, P Sonneveld, P Tosi… - Journal of clinical …, 2005 - szpiczak.org
International Staging System for Multiple Myeloma Page 1 International Staging System for
Multiple Myeloma Philip R. Greipp, Jesus San Miguel, Brian GM Durie, John J. Crowley, Bart …

Radial versus femoral access in patients with acute coronary syndromes undergoing invasive management: a randomised multicentre trial

…, A Zingarelli, N de Cesare, S Rigattieri, P Tosi… - The Lancet, 2015 - thelancet.com
Background It is unclear whether radial compared with femoral access improves outcomes
in unselected patients with acute coronary syndromes undergoing invasive management …

[HTML][HTML] Clinical characteristics and risk factors associated with COVID-19 severity in patients with haematological malignancies in Italy: a retrospective, multicentre …

…, G Visani, MC Tisi, A Tafuri, P Tosi… - The Lancet …, 2020 - thelancet.com
Background Several small studies on patients with COVID-19 and haematological
malignancies are available showing a high mortality in this population. The Italian …

Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after …

…, GL Deliliers, A Ledda, C Cellini, T Caravita, P Tosi… - The Lancet, 2010 - thelancet.com
Background Thalidomide plus dexamethasone (TD) is a standard induction therapy for
myeloma. We aimed to assess the efficacy and safety of addition of bortezomib to TD (VTD) …

[HTML][HTML] Lenalidomide maintenance after autologous stem-cell transplantation in newly diagnosed multiple myeloma: a meta-analysis

…, PG Richardson, C Hulin, P Tosi… - Journal of Clinical …, 2017 - ncbi.nlm.nih.gov
Purpose Lenalidomide maintenance therapy after autologous stem-cell transplantation
(ASCT) demonstrated prolonged progression-free survival (PFS) versus placebo or …

Superiority of thalidomide and dexamethasone over vincristine-doxorubicindexamethasone (VAD) as primary therapy in preparation for autologous transplantation for …

M Cavo, E Zamagni, P Tosi, P Tacchetti, C Cellini… - Blood, 2005 - ashpublications.org
The aim of the present study was to compare thalidomide-dexamethasone (Thal-Dex) and
vincristine-doxorubicin-dexamethasone (VAD) as primary therapy in preparation for …